High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder with high prevalence in patients suffering from chronic liver diseases \[1\]. NAFLD is characterized by the accumulation of \> 5% of fat deposits in hepatocytes (hepatic steatosis) with no known other reasons for steatosis as excessive alcohol intake.The global prevalence of NAFLD differs depending on the population reaching 13% in Africa, 32% in the Middle East, and 30 % in the United States
Epistemonikos ID: 4e49aedec7e65f8b186804957fc3cb6537b3df5e
First added on: May 14, 2024